sanifit-logo-hl

New approach to
calcification disorders

sanifit-portada

Who we are

Sanifit is a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders. The company is a spin-off from the University of the Balearic Islands, and has offices in Spain and the U.S. Sanifit’s lead compound, SNF472, is a novel small molecule, and a selective and potent inhibitor of hydroxyapatite (HAP) crystallization, the final common pathway that leads to vascular calcification. Its clinical development is focused on two indications in End Stage Kidney Disease (ESKD) patients; calciphylaxis and peripheral artery disease (PAD).

The company conducted a Phase 2b trial (CaLIPSO) to assess the effect of SNF472 on slowing arterial calcification, a major risk factor for cardiovascular diseases in patients on dialysis. The trial met its primary endpoint in reducing coronary artery calcium progression in patients treated with SNF472 compared to patients receiving placebo over a 52-week period.

SNF472 is in Phase 3 clinical development for the treatment of calciphylaxis or CUA (calcific uremic arteriolopathy) in ESKD patients that will measure two alternate primary endpoints – wound healing and pain. SNF472 is orphan designated for the treatment of calciphylaxis by FDA and EMA.

A phase 3 trial in Peripheral Arterial Disease in ESKD will launch in 2021. PAD in ESKD is driven by progressive calcification of peripheral arteries and disease progression can lead to reduced walking ability, claudication and amputations.

Leadership

Mr. Antonio Jiménez

General Counsel & VP Operations

 Dr. Claire Padgett

SVP Development Operations

 Dr. Marco Antonio Moreno

VP Manufacturing

Mr. Hans Christian Keller

VP Business Development

 Ms. Marisa Guitart

Head of Business Operations

 Ms. Susan Lundeen

Head of People

Board of directors

Russell G. Greig

Chairman of the Board

Joan Perelló

Managing Director

Pablo Cironi

Board Member

Joël Jean-Mairet

Board Member

Casper Breum

 Board Member

Geert-Jan Mulder

Board Member

Keith R. Leonard

Board Member

Damià Tormo

Board Member

Guy Paul Nohra

 Board Member

Juan Bárcenas - Board member

Juan Bárcena

 Board Member

Funding

Sanifit is backed by a strong syndicate of international investors. These investors include Venture Capital Funds, Corporate Venture Funds and several private investors (Invenzia, Toni and Guillem Ballester, Nefrona Foundation, Somtobir and several ex Phadia and ex Pharmacia employees and directors) represented by MGA.
To date, the company has raised over $130 million equity. The Company ’s main investors include:

Private investors

Public Funds

Número de proyecto: RTC-2014-2460-1
Título: RETOS COLABORACION
Nombre del Ministerio: Ministerio de Ciencia, Innovación y Universidades

LATEST NEWS

  • Sanifit to Participate in Upcoming Investor Conferences in December 2020

      Palma, Spain and San Diego, USA, November 24, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that Joan Perelló, Chief Executive Officer, and Adam Levy, Chief Financial Officer, will participate in two virtual investor conferences in December. Evercore ISI 3rd Annual HealthCONx Virtual Conference Management will participate […]

  • Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports

      Palma, Spain and San Diego, USA, November 10, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, today announces the publication of subgroup analyses from its Phase 2b CaLIPSO clinical study in Kidney International Reports. CaLIPSO studied the effect of SNF472 over 52 weeks on vascular calcification in […]

  • Sanifit to Participate at Upcoming Investor Conferences in November 2020

      Palma, Spain and San Diego, USA, 2 November 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced that Joan Perelló, Chief Executive Officer, and Adam Levy, Chief Financial Officer, will participate in the following virtual investor conferences in November: Credit Suisse 29th Annual Healthcare Conference   Management will […]

  • Sanifit Presents New Data for SNF472 in Treatment of Vascular Calcification at ASN Kidney Week 2020

      Four presentations at oral and ePoster sessions focus on the effect of SNF472 in vascular calcification disorders   Palma, Spain and San Diego, USA, October 22, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, today announced the presentation of new data on lead candidate SNF472 today at […]

  • Sanifit to Present New Data on SNF472 for Vascular Calcification at the American Society of Nephrology Kidney Week 2020

      Palma, Spain and San Diego, USA, October 12, 2020 – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, announced that it will present new data on its lead asset SNF472 at the American Society of Nephrology (ASN) Kidney Week 2020 Annual Meeting on October 22, 2020.  Sanifit will make […]

    Your name (required)

    Phone (required)

    Company

    E-mail (required)

    Comments

    CONTACT

    Sanifit


    SPAIN
    ParcBIT – Ctra Valldemossa km7.4
    Building Europa, 2nd floor
    07121 Palma

     

     +34 971 439 925
     info@sanifit.com

    USA
    3655 Nobel Drive
    Suite #540
    San Diego, CA 92122